Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318915 · ClinicalTrials.gov registry record · Early Phase 1
Research Study of ATG and Rituximab in Renal Transplantation
A Early Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT01318915 is a Early Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 10 participants.
The verdict
NCT01318915, a Early Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
Interventions
- DRUG Sirolimus
- DRUG Rituximab
- DRUG Tacrolimus
- DRUG ATG
- DRUG MMF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-07-25 |
| Est. Completion | 2017-08-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01318915
The ClinicalTrials.gov registry entry for NCT01318915 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sirolimus is the first listed.
NCT01318915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01318915 about?
NCT01318915 is a clinical study titled "Research Study of ATG and Rituximab in Renal Transplantation". The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
What is the current status of trial NCT01318915?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2011-07-25. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT01318915?
The interventions under investigation include: Sirolimus (DRUG), Rituximab (DRUG), Tacrolimus (DRUG), ATG (DRUG), MMF (DRUG).
Who is sponsoring clinical trial NCT01318915?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.